Sukumar Nagendran net worth and biography

Sukumar Nagendran Biography and Net Worth

Insider of Taysha Gene Therapies

Suku brings more than 25 years of experience in gene therapy development, clinical development strategy, medical affairs, diagnostics, payer strategy and commercialization of therapeutic products; also currently advising many other gene therapy and healthcare companies. Formerly of Jaguar Gene Therapy, AveXis, Quest Diagnostics and Pfizer.

What is Sukumar Nagendran's net worth?: The estimated net worth of Sukumar Nagendran is at least $6.07 million as of January 26th, 2026. Nagendran owns 1,317,389 shares of Taysha Gene Therapies stock worth more than $6,073,163 as of February 6th. This net worth approximation does not reflect any other assets that Nagendran may own. Additionally, Nagendran receives a salary of $820,590.00 as Insider at Taysha Gene Therapies. Learn More about Sukumar Nagendran's net worth.
How old is Sukumar Nagendran?: Nagendran is currently 57 years old. There are 2 older executives and no younger executives at Taysha Gene Therapies. Learn More on Sukumar Nagendran's age.
What is Sukumar Nagendran's salary?: As the Insider of Taysha Gene Therapies, Inc., Nagendran earns $820,590.00 per year. The highest earning executive at Taysha Gene Therapies is Mr. Sean P. Nolan, CEO & Chairman, who commands a salary of $925,330.00 per year. Learn More on Sukumar Nagendran's salary.
How do I contact Sukumar Nagendran?: The corporate mailing address for Nagendran and other Taysha Gene Therapies executives is 2280 Inwood Road, DALLAS TX, 75235. Taysha Gene Therapies can also be reached via phone at 214-612-0000 and via email at [email protected]. Learn More on Sukumar Nagendran's contact information.
Has Sukumar Nagendran been buying or selling shares of Taysha Gene Therapies?: During the last quarter, Sukumar Nagendran has sold $1,489,468.98 in shares of Taysha Gene Therapies stock. Most recently, Sukumar Nagendran sold 26,918 shares of the business's stock in a transaction on Monday, January 26th. The shares were sold at an average price of $4.61, for a transaction totalling $124,091.98. Following the completion of the sale, the insider now directly owns 1,317,389 shares of the company's stock, valued at $6,073,163.29. Learn More on Sukumar Nagendran's trading history.
Who are Taysha Gene Therapies' active insiders?: Taysha Gene Therapies' insider roster includes Kamran Alam (CFO), Phillip Donenberg (Director), Paul Manning (Director), Sukumar Nagendran (Insider), Sean Nolan (Director), and R.A. Session, II (CEO). Learn More on Taysha Gene Therapies' active insiders.
Are insiders buying or selling shares of Taysha Gene Therapies?: In the last twelve months, Taysha Gene Therapies insiders bought shares 1 times. They purchased a total of 750,000 shares worth more than $2,062,500.00. In the last twelve months, insiders at the sold shares 10 times. They sold a total of 1,167,140 shares worth more than $5,156,612.66. The most recent insider tranaction occured on January, 26th when insider Sukumar Nagendran sold 26,918 shares worth more than $124,091.98. Insiders at Taysha Gene Therapies own 3.8% of the company. Learn More about insider trades at Taysha Gene Therapies.
Information on this page was last updated on 1/26/2026.

Sukumar Nagendran Insider Trading History at Taysha Gene Therapies

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
1/26/2026	Sell	26,918	$4.61	$124,091.98	1,317,389
1/23/2026	Sell	89,132	$4.75	$423,377.00	1,344,307
1/12/2026	Sell	200,000	$4.71	$942,000.00	1,006,439
12/1/2025	Sell	260,047	$4.51	$1,172,811.97	1,006,439
11/28/2025	Sell	110,125	$4.75	$523,093.75	1,006,439
9/10/2025	Sell	200,000	$3.23	$646,000.00	1,006,439
5/16/2023	Buy	5,000	$0.68	$3,400.00	34,226

Sukumar Nagendran Buying and Selling Activity at Taysha Gene Therapies

Taysha Gene Therapies Company Overview

Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center. Taysha Gene Therapies, Inc. was incorporated in 2019 and is headquartered in Dallas, Texas.

Today's Range

Now: $4.61

$4.44

$4.70

50 Day Range

MA: $5.11

$4.06

$6.00

2 Week Range

Now: $4.61

$1.05

$6.02

Volume

2,637,350 shs

Average Volume

2,710,934 shs

Market Capitalization

$1.26 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.01

Sukumar Nagendran Biography and Net Worth

What is Sukumar Nagendran's net worth?

How old is Sukumar Nagendran?

What is Sukumar Nagendran's salary?

How do I contact Sukumar Nagendran?

Has Sukumar Nagendran been buying or selling shares of Taysha Gene Therapies?

Who are Taysha Gene Therapies' active insiders?

Are insiders buying or selling shares of Taysha Gene Therapies?